Cardiac xenotransplantation

Current Opinion in Cardiology

Volumn 12, Issue 2, 1997, Pages 172-178

  Artrip, John H ^a   Itescu, Silviu ^a   Minanov, Oktavijan P ^a   Kwiatkowski, Pawel A ^a   Michler, Robert E ^a  

^a New York State Psychiat Inst and New York Presbyterian Hospital Columbia University Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT FIXING ANTIBODY; GALACTOSE; REGULATOR PROTEIN;

ARTICLE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; NONHUMAN; PRIMATE; PRIORITY JOURNAL; SWINE; TRANSGENIC ANIMAL; VASCULAR ENDOTHELIUM; XENOTRANSPLANTATION;

EID: 0030947192     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-199703000-00013     Document Type: Article

References (47)

1. Levin HR, Oz MC, Chen JM, Packer M, Rose EA, Burkhoff D: Reversal of chronic ventricular dilation in patients with end-stage cardiomyopathy by prolonged mechanical unloading. Circulation 1995, 91:2717-2720.
2. Calne RY: Organ transplantation between widely disparate species. Transplant Proc 1970, 2:550-556.
3. Galili U, Macher BA, Buehler J, Shohet SB: Human natural anti-α-galactosyl IgG: the specific recognition of α(1,3) linked galactose residues. J Exp Med 1985, 162:573-582. This is the first study to recognize the importance of natural antibody directed against α(1,3)-linked galactose residues.
4. Platt JL, Lindman BJ, Chen H, Spitalnik SL, Bach FH: Endothelial cell antigens recognized by xenoreactive human natural antibodies. Transplantation 1990, 50:817-822.
5. Galili U, Shohet SB, Kobrin E, Stults CM, Macher BA: Man, apes, and old world monkeys differ from other mammals in the expression of α-galactosyl epitopes on nucleated cells. J Biol Chem 1988, 263:17755-17762.
6. Parker WR, Bruno D, Holzknecht ZE, Plat JL: Xenoreactive natural antibodies: isolation and initial characterization. J Immunol 1994, 153:3791-37803.
7. Neething FA, Koren E, Ye Y, Richards SV, Kujundzic M, Oriol R, Cooper DKC: Protection of pig kidney cells from the cytotoxic effect of anti-pig antibodies by α-galactosyl oligosaccharides. Transplantation 1994, 57:959-963.
8. Ye Y, Neethling FA, Niekrasz M, Koren E, Richards SV, Martin M, Kosanke S, Oriol R, Cooper DKC: Evidence that intravenously administered α-galactosyl carbohydrates reduce baboon serum cytotoxicity to pig kidney cells and transplanted pig hearts. Transplantation 1994, 58:330-337.
9. Watier H, Guillaumin J-M, Piller F, Lacord M, Thibault G, Lebranchu Y, Monsigny M, Bardos P: Removal of terminal α-galactosyl residues from xenogeneic porcine endothelial cells. Transplantation 1996, 62:105-113.
10. Sandrin MS, Vaughan HA, Dabkowski PL, McKenzie IFC: Anti-pig IgM antibodies in human serum react predominantly with Gal α1,3-Gal epitopes. Proc Nat Acad Sci U S A 1993, 90:11391-11395. This is a thorough examination of the role of IgM antibodies directed against Gal α1,3-Gal in hyperacute rejection.
11. Kroshus TJ, Bolman RM, Dalmasso AP: Selective IgM depletion prolongs organ survival in an ex vivo model of pig-to-human xenotransplantation. Transplantation 1996, 62:5-12.
12. Magee JC, Collins BH, Harland RC, Lindman BJ, Bollinger RB, Frank MM, Platt JL: Immunoglobulin prevents complement mediated hyperacute rejection in swine-to-primate xenotransplantation. J Clin Invest 1995, 96:2404-2412.
13. Xu H, Edwards NM, Chen JM, Xu D, Michler RE: Age-related development of human anti-pig xenoantibody. J Thorac Cardiovasc Surg 1995, 110:1023-1029.
14. Xu H, Edwards NM, Chen JM, Kwiatkowski PA, Rosenberg SE, Michler RE: Newborn baboon serum lacks natural anti-pig xenoantibody. Transplantation 1995, 59:1189-1194.
15. Kaplon RJ, Michler RE, Xu H, Kwiatkowski PA, Edwards N, Platt JL: Absence of hyperacute rejection in newborn pig-to-baboon cardiac xenografts. Transplantation 1995, 59:1-6. In vivo studies using a newborn model of pig-to-baboon xenotransplantation. In the absence of performed xenoreactive antibody, xenografts survive beyond the hyperacute period.
16. Minanov OP, Itescu S, Neethling FA, Morgenthau A, Kwiatkowski P, Cooper DKC, Michler RE: Anti-gal IgG antibodies in sera of newborn humans and baboons and its significance in pig xenotransplantation. Transplantation 1996, 63:182-186.
17. Michler RE, McManus RP, Smith CR, Sadeghi AN, Marboe CC, Reemtsma K, Rose EA: Prolongation of primate cardiac xenograft survival with cyclosporine. Transplantation 1987, 44:632-636.
18. Norin AJ, Roslin MS, Panza A, Coons MS, Chen CK, Kim YD, Strashun A, Cunningham JN, Tranbaugh RF: TLI induces specific B-cell unresponsiveness and long-term monkey heart xenograft survival in cyclosporine-treated baboons. Transplant Proc 1992, 24:508-510.
19. Leventhal JR, John R, Fryer JP, Witson JC, Derlich JM, Remiszewski J, Dalmasso AP, Matas AJ, Bolman RM: Removal of baboon and human antiporcine IgG and IgM natural antibodies by immunoadsorption. Transplantation 1995, 59:294-300.
20. Blakely ML, Van der Werf, Berndt MC, Dalmasso AP, Bach FH, Hancock WW: Activation of intragraft endothelial and mononuclear cells during discordant xenograft rejection. Transplantation 1994, 58:1059-1066.
21. Itescu S, Kwiatkowski P, Wang SF, Blood T, Minanov OP, Rose S, Michler RE: Circulating human mononuclear cells exhibit augmented lysis of pig endothelium following activation with IL-2. Transplantation 1997, 63:182-186.
22. Shaw AS, Itescu S, O'Hair DP, Tugulea S, Kwiatkowski PA, Liu Z, Platt JL, Rose EA, Suciu-Foca N, Michler RE: Importance of cell-mediated immune responses in rejection of concordant heart xenografts in primates. Transplant Proc 1996, 28:775-776.
23. Alter BJ, Bach FH: Cellular basis of the proliferative response of human T cells to mouse xenoantigens. J Exp Med 1990, 171:333-338.
24. Murray AG, Khodadoust NM, Pober JS, Bothwell AL: Porcine aortic endothelial cells activate human T cells: direct presentation of MHC antigens and costimulation by ligands for human CD2 and CD28. Immunity 1994, 1:57-63. One of the first studies to address T cell immunity across species and ask the question regarding cross-species compatibility of histocompatibility antigens and immune accessory molecules.
25. Rollins SA, Kennedy SP, Chodera AJ, Elliott EA, Zavoico GB, Matis LA: Evidence that activation of human T cells by porcine endothelium involves direct recognition for LFA-1 and CD2. Transplantation 1994, 57:1709-1716.
26. Bravery CA, Batten P, Yacoub M, Rose ML: Direct recognition SLA- and HLA-like class II antigens on porcine endothelium by human T cells results in T cell activation and release of IL-2. Transplantation 1995, 60:1024-1033.
27. Koren E, Milotic F, Neethling FA, Koscec M, Fei D, Kobayashi T, Taniguchi S, Cooper DKC: Monoclonal antiidiotypic antibodies neutralize cytotoxic effects of anti-αGal antibodies. Transplantation 1996, 62:837-843.
28. Leventhal JR, Dalmasso AP, Cromwell JW, Platt JL, Manivel CJ, Bolman RM, Matas AJ: Prolongation of cardiac xenograft survival by depletion of complement. Transplantation 1993, 55:857-866.
29. Pruitt SK, Kirk AD, Bollinger RR, Marsh HC, Collins BH, Levin JL, Mault JR, Heinle JS, Ibrahim S, Rudolph AR, et al.: The effect of soluble complement receptor type 1 on hyperacute xenograft rejection of porcine xenografts. Transplantation 1994, 57:363-370.
30. Kroshus TJ, Rollms SA, Dalmasso AP, Elliott EA, Matis LA, Squinto SP, Bolman RM: Complement inhibition with anti-C5 monoclonal antibody prevents acute cardiac tissue injury in an ex vivo model of pig-to-human xenotransplantation. Transplantation 1995, 60:1194-1202.
31. Brauer RB, Baldwin WM, Wang D, Pruitt SK, Klein AS, Sanfilippo F: Functional activity of anti-C6 antibodies in C6-deficient rats reconstituted by liver allografts: ability to inhibit hyperacute rejection of discordant cardiac xenografts. Transplantation 1996, 61:588-594.
32. Van den Berg CW, Morgan BP: Complement-inhibiting activities of human CD59 and analogues from rat, sheep, and pig are not homologously restricted. J Immunol 1994, 152:4095-4105. This paper refutes the argument against homologous restriction.
33. Diamond LE, McCurry KR, Martin MJ, McClellan SB, Oldham ER, Platt JL, Logan JS: Characterization of transgenic pigs expressing functionally active human CD59 on cardiac endothelium. Transplantation 1996, 61:1241-1249.
34. Fodor WL, Williams BL, Malis LA, Madri JA, Rollins SA, Knight JW, Velander W, Squinto SP: Expression of a functional human complement inhibitor in a transgenic pig as a model for the prevention of xenogeneic hyperacute organ rejection. Proc Nat Acad Sci USA 1994, 91:11153-11157. The development and characterization of transgenic pigs expressing human CD59.
35. McCurry KR, Kooyman DL, Alvarado CG, Cotterell AH, Martin MJ, Logan JS, Platt JL: Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury. Nature Med 1995, 1:423-427. Initial reports of in vivo heterotopic transplanation of transgenic pigs expresing human CRPs into primate donors. Graft survival up to 30 hours is obtained.
36. Rosengard AM, Cary NR, Langford GA, Tucker AW, Wallwork J, White DJG: Tissue expression of human complement inhibitor, decay-accelerating factor, in transgenic pigs. Transplantation 1995, 59:1325-1333.
37. Langford GA, Cozzi E, Yannoutsos N, Lancaster R, Elsome K, Chen P, White DJG: Production of pigs transgenic for human regulators of complement activation using YAC technology. Transplant Proc 1996, 28:862-863.
38. Tearle RG, Tange MJ, Zannettino ZL, Katerelos M, Shinkel TA, Van Denderen BJ, Lonie AJ, Lyons I, Nottle MB, Cox T, et al.: The α1,3-galactosyltransferase knockout mouse: implications for xenotransplantation. Transplantation 1996, 61:13-19. Characterization and development of mice that lack α1,3-galactosyltransferase.
39. Sandrin MS, Fodor WL, Mouhtouris E, Osman M, Cohney S, Rollins SA, Guilmette ER, Setter E, Squinto SP, McKenzie IF: Enzymatic remodeling of the carbohydrate surface of a xenogenic cell substantially reduces human antibody binding and complement-mediated cytolysis. Nature Med 1995, 12:1261-1267. A thorough paper outlining strategies of interrupting the synthetic pathways of α-gal.
40. Sharma A, Okabe J, Birch P, McClellan SB, Martin MJ, Platt JL, Logan JS: Reduction in the level of Gal (alpha 1,3)Gal in transgenic mice and pigs by the expression of an alpha(1,2)fucosyltransferase. Proc Nat Acad Sci U S A 1996, 93:7190-7195.
41. Leventhal JR, Flores HC, Gruber SA, Figueroa J, Platt JL, Manivel JC, Bach FH, Matas AJ, Bolman RM: Evidence that 15-deoxyspergualin inhibits natural antibody production but fails to prevent hyperacute rejection in a discordant xenograft model. Transplantation 1992, 54:26-31.
42. Xiao F, Chong A, Foster P, Sankary H, McChesney L, Koukoulis G, Yang J, Freiders D, Williams JW: Leflunomide controls rejection in hamster-to-rat cardiac xenografts. Transplantation 1994, 58:828-834.
43. Consenza CA, Cramer DV, Tuso PJ, Chapman FA, Wang HK, Makowka L: Combination therapy with brequinar sodium and cyclosporine synergistically prolongs hamster-to-rat cardiac xenograft survival. J Heart Lung Transplant 1994, 13:489-497.
44. Thomas F, Araneda D, Quarantillo P: Long-term survival of disparate cardiac xenografts: induction of tolerance and humoral accommodation. Transplant Proc 1994, 26:1220-1223.
45. O'Hair DP, McManus RP, Komorowski R: Inhibition of chronic vascular rejection in primate cardiac xenografts using mycophenolate mofetil. Ann Thorac Surg 1994, 58:1311-1315.
46. Michler RE, Shah AS, Itescu S, O'Hair DP, Tugulea S, Kwitkowski PA, Liu Z, Platt JL, Rose EA, Suciu-Foca N: The influence of concordant xenografts on the humoral and cell-mediated immune responses to subsequent allografts in primates. J Thorac Cardiovasc Surg 1996, 112:1002-1009. An examination of the influences of xenotransplantation on subsequent allotransplantation and the implications for "bridging strategies."
47. Shimkin MR: The problem of experimentation on human beings: the research worker's point of view. From: Edsall G. A positive approach to the problem of human experimentation. Daedalus 1969, 98:463-479.